Search

Publications

PI3Kβ controls immune evasion in PTEN-deficient breast tumours

PI3Kβ controls immune evasion in PTEN deficient breast tumoursBergholz JS*, Wang Q*, Wang Q*, Ramseier M, Prakadan S, Fang R, Kabraji S, Gray K, Abell-Hart K, Xie S, Guo X, Von T, Jiang T, Freeman G, Kim HJ, Shalek AK, Roberts TM, Zhao JJ. PI3Kβ controls immune evasion in PTEN-deficient breast tumours. Nature. 2023 May;617(7959):139-146. doi: 10.1038/s41586-023-05940-w. PMID: 37076617. PMCID: PMC10494520. *: Contributed equally
https://pubmed.ncbi.nlm.nih.gov/37076617/

 

STING Agonism Reprograms Tumor-associated Macrophages and Overcomes Resistance to PARP inhibition in BRCA1-deficient Models of Breast Cancer

STING Agonism Reprograms Tumor associated Macrophages and Overcomes Resistance to PARP inhibition in BRCA1 deficient Models of Breast CancerWang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, He X, Xie S, Jiang T, Wang W, Zoeller JJ, Kim HJ, Roberts TM, Konstantinopoulos PA, Matulonis UA, Dillon DA, Winer EP, Lin NU, Zhao JJ. STING Agonism Reprograms Tumor-associated Macrophages and Overcomes Resistance to PARP inhibition in BRCA1-deficient Models of Breast Cancer. Nat Commun. 2022 May 31;13(1):3022. doi:10.1038/s41467-022-30568-1. PMID: 35641483; PMCID: PMC9156717.
https://pubmed.ncbi.nlm.nih.gov/35641483/

Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotides

Targeting Oncogenic KRAS with Molecular Brush Conjugated Antisense OligonucleotidesWang D*, Wang Q*, Wang Y, Chen P, Lu X, Jia F, Sun Y, Sun T, Zhang L, Che F, He J, Lian L, Morano G, Shen M, Ren M, Dong SS, Zhao JJ, Zhang K. Targeting Oncogenic KRAS with Molecular Brush-Conjugated Antisense Oligonucleotides. Proc Natl Acad Sci U S A. 2022 Jul 19;119(29): e2113180119. doi: 10.1073/pnas.2113180119. PMID: 35858356; PMCID: PMC9304022. *: Contributed equally
https://pubmed.ncbi.nlm.nih.gov/35858356/

PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

PARP-Inhibition-Elicits-STING-Dependent-Antitumor Immunity in Brca1 Deficient Ovarian CancerDing L*, Kim HJ*, Wang Q*, Kearns M, Jiang T, Ohlson CE, Li BB, Xie S, Liu JF, Stover EH, Howitt BE, Bronson RT, Lazo S, Roberts TM, Freeman GJ, Konstantinopoulos PA, Matulonis UA, Zhao JJ. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer. Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054. PMID: 30540933; PMCID: PMC6366450. *: Contributed equally
https://pubmed.ncbi.nlm.nih.gov/30540933/

Receptor-Interacting Protein Kinase 3 Contributes to Abdominal Aortic Aneurysms via Smooth Muscle Cell Necrosis and Inflammation.

Receptor Interacting-Protein Kinase 3 Contributes to Abdominal Aortic Aneurysms via Smooth Muscle Cell-Necrosis and InflammationWang Q, Liu Z, Ren J, Morgan S, Assa C, Liu B. Receptor-Interacting Protein Kinase 3 Contributes to Abdominal Aortic Aneurysms via Smooth Muscle Cell Necrosis and Inflammation. Circ Res. 2015 Feb 13;116(4):600-11. doi: 10.1161/CIRCRESAHA.116.304899. PMID: 25563840; PMCID: PMC4329096.
https://pubmed.ncbi.nlm.nih.gov/25563840/

 

Complete List of Published Work in MyBibliography:
https://www.ncbi.nlm.nih.gov/myncbi/qiwei.wang.1/bibliography/public/